Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors

Trial Profile

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Lurbinectedin (Primary) ; Bevacizumab; Paclitaxel
  • Indications Breast cancer; Cervical cancer; Head and neck cancer; Lung cancer; Ovarian cancer; Solid tumours; Uterine cancer
  • Focus Adverse reactions
  • Sponsors PharmaMar
  • Most Recent Events

    • 31 Aug 2017 According to a PharmaMar media release, new clinical data will be presented at the European Society of Medical Oncology (ESMO) congress 2017.
    • 31 Aug 2017 Results published in a PharmaMar Media Release.
    • 11 Oct 2016 Results (data cut off April 2016) presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top